Shire PLC (SHPG) Stock Rating Lowered by Liberum Capital

Liberum Capital cut shares of Shire PLC (NASDAQ:SHPG) from a buy rating to a hold rating in a research note released on Thursday, June 1st, Marketbeat Ratings reports.

A number of other analysts have also weighed in on SHPG. Guggenheim reissued a neutral rating on shares of Shire PLC in a report on Friday, February 17th. Jefferies Group LLC set a $239.00 price target on shares of Shire PLC and gave the company a buy rating in a report on Friday, February 17th. Barclays PLC started coverage on shares of Shire PLC in a report on Tuesday, March 7th. They issued an overweight rating for the company. Royal Bank Of Canada reissued a buy rating and issued a $221.00 price target on shares of Shire PLC in a report on Tuesday, March 14th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a focus list rating on shares of Shire PLC in a report on Tuesday, March 21st. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $223.01.

Shire PLC (SHPG) opened at 172.98 on Thursday. The stock has a market cap of $51.52 billion, a P/E ratio of 177.42 and a beta of 1.57. Shire PLC has a 1-year low of $161.09 and a 1-year high of $209.22. The company’s 50-day moving average price is $176.62 and its 200-day moving average price is $174.09.

Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.22 by $0.41. The company had revenue of $3.57 billion during the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The business’s revenue was up 109.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.12 EPS. Analysts predict that Shire PLC will post $14.90 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2017/06/25/shire-plc-shpg-stock-rating-lowered-by-liberum-capital-updated.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Whittier Trust Co. raised its position in shares of Shire PLC by 19.1% in the first quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 92 shares during the period. Pinnacle Bank bought a new position in shares of Shire PLC during the first quarter worth approximately $101,000. Thompson Davis & CO. Inc. raised its position in shares of Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 19 shares during the period. Sowell Financial Services LLC bought a new position in shares of Shire PLC during the fourth quarter worth approximately $126,000. Finally, FTB Advisors Inc. raised its position in shares of Shire PLC by 11.1% in the first quarter. FTB Advisors Inc. now owns 749 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 75 shares during the period. Institutional investors own 20.93% of the company’s stock.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply